|
GENTAUR
Tel: +32 16 58 90 45
Fax: + 32 16 50 90 45
info@genprice.com
Av. de l'Armée 68
• B-1040 BRUSSELS • BELGIUM
GENTAUR FRANCE
Tel: 01 43 25 01 50
9, Rue Lagrange
• 75005 PARIS • FRANCE
| |
T-6504 Tyrphostin AG 1295, >99%
[AG 1295] [6,7-Dimethyl-2-phenylquinoxaline]
| M.W. 234.30 |
C16H14N2
|
[71897-07-9] |
Storage: Store at or below -20 ºC. Solubility:
Soluble in DMSO. Appearance: Off-white solid. Disposal:
A
 | Selectively inhibits PDGF receptor autophosphorylation (IC50
= 0.3-0.5 µM). Levitzki, A. and Gazit, A. "Tyrosine kinase inhibition: an
approach to drug development." Science 267: 1782-1788 (1995).
|
| Selectively inhibits PDGF dependent DNA synthesis. Bilder, G.E., et
al. "Tyrphostins inhibit PDGF-induced DNA synthesis and associated
early events in smooth muscle cells." Am. J. Physiol. 260:
C721-C730 (1991). Kovalenko, M., et al. "Selective platelet-derived
growth factor receptor kinase blockers reverse cis-transformation."
Cancer Res. 54: 6106-6114 (1994). |
| Potent inhibitor of human and porcine smooth muscle cell (SMC)
proliferation in vitro and of rat SMC proliferation in vivo.
Banai, S., et al. "PDGF-receptor tyrosine kinase blocker AG1295
selectively attenuates smooth muscle cell growth in vitro and reduces
neointimal formation after ballon angioplasty in swine." Circulation
97: 1960-1969 (1998). Fishbein, I., et al. "Nanoparticulate
delivery system of a tyrphostin for the treatment of restenosis." J.
Control Release 65: 221-229 (2000). Karck, M., et al.
"Inhibition of aortic allograft vasculopathy by local delivery of
platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295."
Transplantation 74: 1335-1341 (2002). |
|
